Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

4.605 -0.085 (-1.81%)
Streaming Delayed Price Updated: 10:49 AM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,927
Open 4.510
Bid (Size) 4.600 (4)
Ask (Size) 4.670 (1)
Prev. Close 4.690
Today's Range 4.510 - 4.750
52wk Range 3.810 - 15.97
Shares Outstanding 113,793,338
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire

Performance

YTD
-1.8%
-1.8%
1 Month
-7.9%
-7.9%
3 Month
-1.8%
-1.8%
6 Month
-49.7%
-49.7%
1 Year
-67.6%
-67.6%

More News

Read More
Earnings Scheduled For March 26, 2025
Via Benzinga
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
From Precision BioSciences, Inc.
Via Business Wire
Assessing Precision BioSciences: Insights From 4 Financial Analysts
Via Benzinga
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
From Precision BioSciences, Inc.
Via Business Wire
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
Via Benzinga
Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
From Precision BioSciences, Inc.
Via Business Wire
iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
From iECURE, Inc.
Via Business Wire
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming November Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
From Precision BioSciences
Via Business Wire
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Third Quarter Results on November 4, 2024
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
From Precision BioSciences, Inc.
Via Business Wire

Frequently Asked Questions

Is Precision BioSciences, Inc. - Common Stock publicly traded?
Yes, Precision BioSciences, Inc. - Common Stock is publicly traded.
What exchange does Precision BioSciences, Inc. - Common Stock trade on?
Precision BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Precision BioSciences, Inc. - Common Stock?
The ticker symbol for Precision BioSciences, Inc. - Common Stock is DTIL on the Nasdaq Stock Market
What is the current price of Precision BioSciences, Inc. - Common Stock?
The current price of Precision BioSciences, Inc. - Common Stock is 4.605
When was Precision BioSciences, Inc. - Common Stock last traded?
The last trade of Precision BioSciences, Inc. - Common Stock was at 04/03/25 10:49 AM ET
What is the market capitalization of Precision BioSciences, Inc. - Common Stock?
The market capitalization of Precision BioSciences, Inc. - Common Stock is 524.03M
How many shares of Precision BioSciences, Inc. - Common Stock are outstanding?
Precision BioSciences, Inc. - Common Stock has 524M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.